Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Christine Shing Wei Law & Keng Yoon Yeong. (2022) Current trends of benzothiazoles in drug discovery: a patent review (2015–2020). Expert Opinion on Therapeutic Patents 32:3, pages 299-315.
Read now
Read now
Articles from other publishers (18)
Jinyong He, Cuicui Xiao, Cuiping Li, Fan Yang & Cong Du. (2023) Integrative analysis of bulk and single-cell RNA sequencing data reveals distinct subtypes of MAFLD based on N1-methyladenosine regulator expression. Liver Research 7:2, pages 145-155.
Crossref
Crossref
Zilu Cheng, Yixiong Chen, Bernd Schnabl, Huikuan Chu & Ling Yang. (2023) Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets. Journal of Advanced Research.
Crossref
Crossref
Xiaofei Xin, Jingjing Li, Wantao Wu, Pengbo Zhao, Yang Yang, Ying Zhu, Lianjie Ren, Chao Qin & Lifang Yin. (2023) ROS-scavenging nanomedicine for “multiple crosstalk” modulation in non-alcoholic fatty liver disease. Biomaterials Science 11:10, pages 3709-3725.
Crossref
Crossref
Qingfu Dong, Haolin Bao, Jiangang Wang, Wujiang Shi, Xinlei Zou, Jialin Sheng, Jianjun Gao, Canghai Guan, Haoming Xia, Jinglin Li, Pengcheng Kang, Yi Xu, Yunfu Cui & Xiangyu Zhong. (2023) Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies. Frontiers in Medicine 10.
Crossref
Crossref
Raul C. Camacho, David Polidori, Tao Chen, Bin Chen, Helen Han Hsu, Bin Gao, Mathieu Marella, Mariusz Lubomirski, Traymon Beavers, Javier Cabrera, Peggy Wong & Andrea R. Nawrocki. (2023)
Validation of a diet‐induced
Macaca fascicularis
model of non‐alcoholic steatohepatitis with dietary and pioglitazone interventions
. Diabetes, Obesity and Metabolism 25:4, pages 1068-1079.
Crossref
Crossref
Wenjing Xu, Changting Cui, Chunmei Cui, Zhenzhen Chen, Haizeng Zhang, Qinghua Cui, Guoheng Xu, Jianglin Fan, Yu Han, Liangjie Tang, Giovanni Targher, Christopher D. Byrne, Ming‐Hua Zheng, Liming Yang, Jun Cai & Bin Geng. (2022) Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. Hepatology 76:6, pages 1794-1810.
Crossref
Crossref
E. Roeb, A. Canbay, H. Bantel, J. Bojunga, J. de Laffolie, M. Demir, U. W. Denzer, A. Geier, W. P. Hofmann, C. Hudert, T. Karlas, M. Krawczyk, T. Longerich, T. Luedde, M. Roden, J. Schattenberg, M. Sterneck, A. Tannapfel, P. Lorenz & F. Tacke. (2022) Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. Zeitschrift für Gastroenterologie 60:09, pages 1346-1421.
Crossref
Crossref
Sara Karjoo, Anthony Auriemma, Teresa Fraker & Harold Edward Bays. (2022) Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 3, pages 100027.
Crossref
Crossref
David A. Rudnick, Jiansheng Huang, Tunda Hidvegi, Andrew S. Chu, Pamela Hale, Admire Munanairi, Dennis J. Dietzen, Paul F. Cliften, Eric Tycksen, Andrew J. Lutkewitte, Brian N. Finck, Stephen C. Pak, Gary A. Silverman & David H. Perlmutter. (2022) Regulation of PGC1α Downstream of the Insulin Signaling Pathway Plays a Role in the Hepatic Proteotoxicity of Mutant α1-Antitrypsin Deficiency Variant Z. Gastroenterology 163:1, pages 270-284.
Crossref
Crossref
Ting-ying Jiao, Yuan-di Ma, Xiao-zhen Guo, Yun-fei Ye & Cen Xie. (2022) Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacologica Sinica 43:5, pages 1103-1119.
Crossref
Crossref
Costanza Renata Neri, Serena Scapaticci, Francesco Chiarelli & Cosimo Giannini. (2022) Liver Steatosis: A Marker of Metabolic Risk in Children. International Journal of Molecular Sciences 23:9, pages 4822.
Crossref
Crossref
Alessandro Mantovani, Christopher D Byrne & Giovanni Targher. (2022) Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology & Hepatology 7:4, pages 367-378.
Crossref
Crossref
Danae Stella Zareifi, Odysseas Chaliotis, Nafsika Chala, Nikos Meimetis, Maria Sofotasiou, Konstantinos Zeakis, Eirini Pantiora, Antonis Vezakis, George K. Matsopoulos, Georgios Fragulidis & Leonidas G. Alexopoulos. (2022) A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease. iScience 25:3, pages 103890.
Crossref
Crossref
Valentin Metzner, Gloria Herzog, Tobias Heckel, Thorsten Bischler, Julia Hasinger, Christoph Otto, Martin Fassnacht, Andreas Geier, Florian Seyfried & Ulrich Dischinger. (2022) Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. Journal of Clinical Medicine 11:3, pages 753.
Crossref
Crossref
Sarah Da Won Bae, Jacob George & Liang Qiao. (2022) From MAFLD to hepatocellular carcinoma and everything in between. Chinese Medical Journal 135:5, pages 547-556.
Crossref
Crossref
Weiyi Qu, Tengfei Ma, Jingjing Cai, Xiaojing Zhang, Peng Zhang, Zhigang She, Feng Wan & Hongliang Li. (2021) Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Frontiers in Medicine 8.
Crossref
Crossref
Christoph G Dietrich, Monika Rau & Andreas Geier. (2021) Screening for nonalcoholic fatty liver disease-when, who and how?. World Journal of Gastroenterology 27:35, pages 5803-5821.
Crossref
Crossref
Rumei Li, Anna Palmiotti, Hilde D. de Vries, Milaine V. Hovingh, Martijn Koehorst, Niels L. Mulder, Yue Zhang, Kim Kats, Vincent W. Bloks, Jingyuan Fu, Henkjan J. Verkade, Jan Freark de Boer & Folkert Kuipers. (2021) Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70−/− mice by reducing fat absorption. Journal of Lipid Research 62, pages 100134.
Crossref
Crossref